EX-99.1 2 ex-99d1.htm EX-99.1 prqr_Ex99_1

Table of Contents

Exhibit 99.1

 

Table of Contents

PAGE 1

Unaudited Condensed Consolidated Financial Statements

 

 

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Financial Position

Click or tap here to enter text.

 

 

 

 

 

 

 

 

 

 

    

December 31, 

    

December 31, 

 

 

2019

 

2018

 

 

€ 1,000

 

€ 1,000

Assets

 

  

 

  

Current assets

 

  

 

  

Cash and cash equivalents

 

111,950

 

105,580

Prepayments and other receivables

 

1,866

 

1,544

Social securities and other taxes

 

850

 

1,243

 

 

 

 

 

Total current assets

 

114,666

 

108,367

 

 

 

 

 

Property, plant and equipment

 

2,440

 

1,864

Investments in associates

 

429

 

 —

 

 

 

 

 

Total assets

 

117,535

 

110,231

 

 

 

 

 

Equity and liabilities

 

  

 

  

Equity

 

 

 

  

Equity attributable to owners of the Company

 

94,329

 

92,915

Non-controlling interests

 

(496)

 

(230)

Total equity

 

93,833

 

92,685

 

 

 

 

 

Current liabilities

 

  

 

  

Borrowings

 

343

 

 —

Lease liabilities

 

508

 

 —

Trade payables

 

445

 

135

Current income tax liability

 

64

 

 —

Social securities and other taxes

 

108

 

 —

Pension premiums

 

 2

 

 7

Deferred income

 

711

 

545

Other current liabilities

 

8,812

 

7,473

 

 

 

 

 

Total current liabilities

 

10,993

 

8,160

 

 

 

 

 

Borrowings

 

12,709

 

9,386

 

 

 

 

 

Total liabilities

 

23,702

 

17,546

 

 

 

 

 

Total equity and liabilities

 

117,535

 

110,231

 

The notes are an integral part of these condensed consolidated financial statements.

 

 

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 2

Unaudited Condensed Consolidated Financial Statements

 

 

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Profit or Loss and OCI

(€ in thousands, except share and per share data)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three month period

 

Year

 

 

ended December 31, 

 

ended December 31, 

 

 

 

 

 

 

 

 

 

 

    

2019

    

2018

    

2019

    

2018

 

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

Other income

 

424

 

1,333

 

1,933

 

5,761

 

 

 

 

 

 

 

 

 

Research and development costs

 

(13,931)

 

(9,542)

 

(46,491)

 

(29,514)

General and administrative costs

 

(3,917)

 

(4,640)

 

(12,887)

 

(12,540)

 

 

  

 

  

 

  

 

  

Total operating costs

 

(17,848)

 

(14,182)

 

(59,378)

 

(42,054)

 

 

  

 

  

 

  

 

  

Operating result

 

(17,424)

 

(12,849)

 

(57,445)

 

(36,293)

Finance income and expense

 

(937)

 

(128)

 

402

 

(792)

Results related to associates

 

(150)

 

 —

 

429

 

 —

 

 

  

 

  

 

  

 

  

Result before corporate income taxes

 

(18,511)

 

(12,977)

 

(56,614)

 

(37,085)

Income taxes

 

(68)

 

 —

 

(132)

 

(1)

 

 

  

 

  

 

  

 

  

Result for the period

 

(18,579)

 

(12,977)

 

(56,746)

 

(37,086)

Other comprehensive income

 

(78)

 

(13)

 

43

 

(28)

 

 

  

 

  

 

  

 

  

Total comprehensive income (attributable to owners of the Company)

 

(18,657)

 

(12,990)

 

(56,703)

 

(37,114)

 

 

 

 

 

 

 

 

 

Result attributable to

 

  

 

  

 

  

 

  

Owners of the Company

 

(18,534)

 

(12,944)

 

(56,480)

 

(36,894)

Non-controlling interests

 

(45)

 

(33)

 

(266)

 

(192)

 

 

(18,579)

 

(12,977)

 

(56,746)

 

(37,086)

 

 

  

 

  

 

  

 

  

Share information

 

  

 

  

 

  

 

  

Weighted average number of shares outstanding1

 

47,372,744

 

38,809,784

 

41,037,244

 

34,052,520

 

 

 

 

 

 

 

 

 

Earnings per share attributable to the equity holders of the Company (expressed in Euro per share)

 

 

 

 

 

 

 

 

Basic loss per share1

 

(0.39)

 

(0.33)

 

(1.38)

 

(1.08)

Diluted loss per share1

 

(0.39)

 

(0.33)

 

(1.38)

 

(1.08)

 

The notes are an integral part of these condensed consolidated financial statements.

1.

For this period presented in these financial statements, the potential exercise of share options is not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in this period.

 

 

 

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 3

Unaudited Condensed Consolidated Financial Statements

 

 

PROQR THERAPEUTICS N.V.
Unaudited Condensed
Consolidated Statement of Changes in Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Attributable to owners of the Company

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity settled

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Employee

 

 

 

 

 

 

 

Non-

 

 

 

 

Number of

 

Share

 

Share

 

Benefit

 

Translation

 

Accumulated

 

 

 

controlling

 

Total

 

 

shares

 

Capital

 

Premium

 

Reserve

 

Reserve

 

Deficit

 

Total

 

interests

 

Equity

 

 

  

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

Balance at January 1, 2018

 

36,425,014

 

1,457

 

148,763

 

8,377

 

136

 

(119,370)

 

39,363

 

(38)

 

39,325

Result for the period

 

 —

 

 —

 

 —

 

 —

 

 —

 

(36,894)

 

(36,894)

 

(192)

 

(37,086)

Other comprehensive income

 

 —

 

 —

 

 —

 

 —

 

(28)

 

 —

 

(28)

 

 —

 

(28)

Recognition of share-based payments

 

 112,473

 

 4

 

2,185

 

3,224

 

 —

 

 —

 

5,413

 

 —

 

5,413

Issuance of ordinary shares

 

6,612,500

 

265

 

83,926

 

 —

 

 —

 

 —

 

84,191

 

 —

 

84,191

Treasury shares transferred

 

(226,098)

 

 —

 

 —

 

 —

 

 —

 

 —

 

 —

 

 —

 

 —

Share options lapsed

 

 —

 

 —

 

 —

 

(97)

 

 —

 

97

 

 —

 

 —

 

 —

Share options exercised

 

226,098

 

 —

 

870

 

(724)

 

 —

 

724

 

870

 

 —

 

870

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at December 31, 2018

 

43,149,987

 

1,726

 

235,744

 

10,780

 

108

 

(155,443)

 

92,915

 

(230)

 

92,685

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 1, 2019

 

43,149,987

 

1,726

 

235,744

 

10,780

 

108

 

(155,443)

 

92,915

 

(230)

 

92,685

Result for the period

 

 —

 

 —

 

 —

 

 —

 

 —

 

(56,480)

 

(56,480)

 

(266)

 

(56,746)

Other comprehensive income

 

 —

 

 —

 

 —

 

 —

 

43

 

 —

 

43

 

 —

 

43

Recognition of share-based payments

 

371,306

 

15

 

3,145

 

5,948

 

 —

 

 —

 

9,108

 

 —

 

9,108

Issuance of ordinary shares

 

10,454,545

 

418

 

48,132

 

 —

 

 —

 

 —

 

48,550

 

 —

 

48,550

Treasury shares transferred

 

(46,900)

 

 —

 

 —

 

 —

 

 —

 

 —

 

 —

 

 —

 

 —

Share options lapsed

 

 —

 

 —

 

 —

 

(44)

 

 —

 

44

 

 —

 

 —

 

 —

Share options exercised

 

46,900

 

 —

 

193

 

(133)

 

 —

 

133

 

193

 

 —

 

193

 

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

 

  

Balance at December 31, 2019

 

53,975,838

 

2,159

 

287,214

 

16,551

 

151

 

(211,746)

 

94,329

 

(496)

 

93,833

 

 

The notes are an integral part of these condensed consolidated financial statements

 

 

 

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 4

Unaudited Condensed Consolidated Financial Statements

 

 

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows

Click or tap here to enter text.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three month period 

 

Year

 

 

ended December 31, 

 

ended December 31, 

 

 

 

 

 

 

 

 

 

 

    

2019

    

2018

    

2019

    

2018

 

 

€ 1,000

 

€ 1,000

 

€ 1,000

 

€ 1,000

Cash flows from operating activities

 

  

 

  

 

  

 

  

Net result

 

(18,579)

 

(12,978)

 

(56,746)

 

(37,086)

Adjustments for:

 

 

 

 

 

 

 

 

— Depreciation

 

509

 

267

 

2,052

 

992

— Share-based compensation

 

4,494

 

3,168

 

9,108

 

5,413

— Financial income and expenses

 

937

 

128

 

(402)

 

792

— Results related to associates

 

150

 

 —

 

(429)

 

 —

— Net foreign exchange gain / (loss)

 

(79)

 

(13)

 

43

 

(28)

 

 

 

 

 

 

 

 

 

Changes in working capital

 

39

 

220

 

1,783

 

1,295

Cash used in operations

 

(12,529)

 

(9,208)

 

(44,591)

 

(28,622)

 

 

  

 

  

 

  

 

  

Corporate income tax paid

 

 —

 

 —

 

(64)

 

(1)

Interest received

 

582

 

105

 

758

 

130

Interest paid

 

(9)

 

 —

 

(73)

 

 —

 

 

  

 

  

 

  

 

  

Net cash used in operating activities

 

(11,956)

 

(9,103)

 

(43,970)

 

(28,493)

 

 

  

 

  

 

  

 

  

Cash flow from investing activities

 

  

 

  

 

  

 

  

Purchases of property, plant and equipment

 

(239)

 

(27)

 

(580)

 

(312)

 

 

  

 

  

 

  

 

  

Net cash used in investing activities

 

(239)

 

(27)

 

(580)

 

(312)

 

 

  

 

  

 

  

 

  

Cash flow from financing activities

 

  

 

  

 

  

 

  

Proceeds from issuance of shares, net of transaction costs

 

48,550

 

(104)

 

48,550

 

84,191

Proceeds from exercise of share options

 

27

 

210

 

193

 

870

Proceeds from borrowings

 

2,027

 

163

 

2,027

 

264

Proceeds from convertible loans

 

 —

 

702

 

690

 

1,132

Repayment of lease liability

 

(400)

 

 —

 

(1,261)

 

 —

 

 

  

 

  

 

 

 

  

Net cash (used in)/generated by financing activities

 

50,204

 

971

 

50,199

 

86,457

 

 

  

 

  

 

  

 

  

Net increase/(decrease) in cash and cash equivalents

 

38,009

 

(8,159)

 

5,649

 

57,652

 

 

  

 

  

 

  

 

  

Currency effect cash and cash equivalents

 

(851)

 

23

 

721

 

(171)

Cash and cash equivalents, at beginning of the period

 

74,792

 

113,716

 

105,580

 

48,099

 

 

  

 

  

 

  

 

  

Cash and cash equivalents at the end of the period

 

111,950

 

105,580

 

111,950

 

105,580

 

The notes are an integral part of these condensed consolidated financial statements.

 

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 5

Unaudited Condensed Consolidated Financial Statements

 

 

PROQR THERAPEUTICS N.V.
Notes to Unaudited Condensed Consolidated Financial Statements

1. General information

ProQR Therapeutics N.V., or “ProQR” or the “Company”, is a development stage company domiciled in the Netherlands that primarily focuses on the development and commercialization of novel therapeutic medicines.

Since September 18, 2014, the Company’s ordinary shares are listed on the NASDAQ Global Market under ticker symbol PRQR.

The Company was incorporated in the Netherlands, on February 21, 2012 and was reorganized from a private company with limited liability to a public company with limited liability on September 23, 2014. The Company has its statutory seat in Leiden, the Netherlands. The address of its headquarters and registered office is Zernikedreef 9, 2333 CK Leiden, the Netherlands.

ProQR Therapeutics N.V. is the ultimate parent company of the following entities:

·

ProQR Therapeutics Holding B.V. (100%);

·

ProQR Therapeutics I B.V. (100%);

·

ProQR Therapeutics II B.V. (100%);

·

ProQR Therapeutics III B.V. (100%);

·

ProQR Therapeutics IV B.V. (100%);

·

ProQR Therapeutics VI B.V. (100%);

·

ProQR Therapeutics VII B.V. (100%);

·

ProQR Therapeutics VIII B.V. (100%);

·

ProQR Therapeutics IX B.V. (100%);

·

ProQR Therapeutics I Inc. (100%);

·

Amylon Therapeutics B.V. (80%);

·

Amylon Therapeutics Inc.  (80%);

 

ProQR Therapeutics N.V. is also statutory director of Stichting Bewaarneming Aandelen ProQR (“ESOP Foundation”) and has full control over this entity. ProQR Therapeutics N.V. holds a 20% minority shareholding in Wings Therapeutics Inc.

As used in these condensed consolidated financial statements, unless the context indicates otherwise, all references to “ProQR” or the “Company” refer to ProQR Therapeutics N.V. including its subsidiaries and the ESOP Foundation.

2. Significant Accounting Policies

These condensed consolidated financial statements have been prepared in accordance with IAS 34 - Interim Financial Reporting. Certain information and disclosures normally included in financial statements prepared in accordance with IFRS have been condensed or omitted. Accordingly, these condensed consolidated financial statements should be read in conjunction with the Company’s annual financial statements for the year ended December 31, 2018. In the opinion of management, all adjustments, consisting of normal recurring nature, considered necessary for a fair presentation have been included in the condensed consolidated financial statements.

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 6

Unaudited Condensed Consolidated Financial Statements

 

 

The Company’s financial results have varied substantially, and are expected to continue to vary, from period to period. The Company believes that its ordinary activities are not linked to any particular seasonal factors.

The Company operates in one reportable segment, which comprises the discovery and development of innovative, RNA based therapeutics.

3. Adoption of new and revised International Financial Reporting Standards

The accounting policies adopted in the preparation of the condensed consolidated financial statements are consistent with those applied in the preparation of the Company’s annual financial statements for the year ended December 31, 2018, except for the change in accounting policies resulting from the implementation of IFRS 16 Leases.  

IFRS 16 specifies how an entity recognizes, measures, presents and discloses leases. The standard provides a single lessee accounting model, requiring lessees to recognize assets and liabilities for all leases unless the lease term is 12 months or less or the underlying asset has a low value. Upon implementation of the standard on January 1, 2019, the Company recognized a lease liability and a corresponding right-of-use asset. As at December 31, 2019, the carrying amount of the lease liability is € 0.5 million and the carrying amount of the right-of-use asset is € 0.6 million
The impact on the income statement is that operating expenses are replaced by depreciation expenses on the right-of-use asset and interest expenses on the lease liability. The main impact on the statement of cash flows is higher cash flows from operating activities, since cash payments for the principal part of the lease liability are classified as cash flows used in financing activities, whereas such payments were previously classified as cash flows used in operating activities. (effect on the year ended December 31, 2019: € 1.3 million).

Other new Standards and Interpretations, which became effective as of January 1, 2019, did not have a material impact on our condensed consolidated financial statements.

4. Critical Accounting Estimates and Judgments

In the application of the Company’s accounting policies, management is required to make judgments, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

(a) Share-based payments

Share options granted to employees and consultants are measured at the fair value of the equity instruments granted. Fair value is determined through the use of the Black-Scholes option-pricing model, which is considered the most appropriate model for this purpose by management.

Initially, the Company’s ordinary shares were not publicly traded and consequently the Company needed to estimate the fair value of its share and the expected volatility of that value. Please refer to the Company’s annual financial statements for the year ended December 31, 2018 for the assumptions used in those estimates. The value of the underlying shares

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 7

Unaudited Condensed Consolidated Financial Statements

 

 

was determined on the basis of the prior sale of company stock method. As such, the Company has benchmarked the value per share to external transactions of Company shares and external financing rounds.

For options granted from the moment of listing, the Company uses the closing price of the ordinary shares on the previous business day as exercise price of the options granted.

The result of the share option valuations and the related compensation expense is dependent on the model and input parameters used. Even though Management considers the fair values reasonable and defensible based on the methodologies applied and the information available, others might derive a different fair value for the Company’s share options.

(b) Corporate income taxes

The Company recognizes deferred tax assets arising from unused tax losses or tax credits only to the extent that the Company has sufficient taxable temporary differences or there is convincing evidence that sufficient taxable profit will be available against which the unused tax losses or unused tax credits can be utilized. Management’s judgment is that such convincing evidence is currently not sufficiently available and a deferred tax asset is therefore only recognized to the extent that the Company has sufficient taxable temporary differences.

(c) Grant income

Grant income is not recognized until there is reasonable assurance that the Company will comply with the conditions attached to them. Grants are recognized in profit or loss on a systematic basis over the period the Company recognizes as expenses the related costs for which the grants are expected to compensate.

(d) Research and development expenditures

Research expenditures are currently not capitalized but are reflected in the income statement because the criteria for capitalization are not met. At each balance sheet date, the Company estimates the level of service performed by the vendors and the associated costs incurred for the services performed.

Although we do not expect the estimates to be materially different from amounts actually incurred, the understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and could result in reporting amounts that are too high or too low in any particular period.

 

5. Cash and Cash Equivalents

At December 31, 2019, the Company’s cash and equivalents were € 111,950,000 as compared to € 105,580,000 at December 31, 2018. The cash balances are held at banks with investment grade credit ratings. The cash at banks is at full disposal of the Company.

 

6. Current liabilities

At December 31, 2019 and December 31, 2018, the other current liabilities consisted principally of accruals for services provided by vendors not yet billed, payroll related accruals and other miscellaneous liabilities.

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 8

Unaudited Condensed Consolidated Financial Statements

 

 

 

7. Borrowings

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 

 

December 31, 

 

    

2019

    

2018

 

 

€ 1,000

 

€ 1,000

Innovation credit

 

7,191

 

5,164

Accrued interest on innovation credit

 

3,124

 

2,351

Convertible notes

 

2,473

 

1,783

Accrued interest on convertible notes

 

264

 

88

 

 

  

 

  

Total borrowings

 

13,052

 

9,386

Current portion

 

(343)

 

 —

 

 

12,709

 

9,386

 

On June 1, 2012, ProQR was awarded an Innovation credit by the Dutch government, through its agency RVO of the Ministry of Economic Affairs, for the Company’s cystic fibrosis program. Amounts were drawn under this facility in the course of the years 2013 through 2017. The credit covered 35% of the costs incurred in respect of the program up to € 5.0 million.

 

The credit is interest-bearing at a rate of 10% per annum. Early October 2018 ProQR received a conditional waiver of the €5 million Innovation credit. Consequently, the repayment of the total loan of €8.1 million, including interest, has been waived if conditions are met, which will be reviewed annually for 3 years. The assets which are co-financed with the granted innovation credit are subject to a right of pledge for the benefit of RVO.

 

On December 10, 2018 ProQR was awarded an Innovation credit for the sepofarsen program. Amounts will be drawn under this facility from 2018 through 2021. The credit of € 4.7 million through December 31, 2021 will be used to conduct the Phase 2/3 clinical study and efforts to obtain regulatory and ethical market approval (NDA/MAA) of sepofarsen

for LCA10, of which €2.2 million has been received at December 31, 2019. The credit, including accrued interest of 10% per annum, is repayable depending on obtaining market approval.

 

Convertible loans

Convertible loans were issued to Amylon Therapeutics B.V. and are interest-bearing at an average rate of 8% per annum. They are convertible into a variable number of ordinary shares within 36 months at the option of the holder or the Company in case financing criteria are met. Any unconverted loans become payable on demand after 24 – 36 months in equal quarterly terms.

8. Shareholders’ equity

The authorized share capital of the Company amounting to € 7,200,000 consists of 90,000,000 ordinary shares and 90,000,000 preference shares with a par value of € 0.04 per share. At December 31, 2019,  53,975,838 ordinary shares were issued and fully paid in cash, of which 4,230,151 were held by the Company as treasury shares  (December 31, 2018:  4,277,051).

 

In November 2018, the Company issued 112,473 shares in the aggregate amount of $2.5 million, at $22.23  (€19.46) per share to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, an upfront payment in ordinary shares to its common stock, was made to Ionis upon signing the worldwide license agreement. The Company was granted an exclusive worldwide license to QR-1123 and relevant patents. The Company will also make future milestone payments, certain of which will be made in equity and others in cash or equity at the company’s discretion, and royalties on net sales of 20% through the royalty term.

 

On November 7, 2018, the Company filed a shelf registration statement, which permitted: (a) the offering, issuance and sale by the Company of up to a maximum aggregate offering price of $ 300,000,000 of its ordinary shares, warrants

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 9

Unaudited Condensed Consolidated Financial Statements

 

 

and/or units; and (b) as part of the $ 300,000,000, the offering, issuance and sale by us of up to a maximum aggregate offering price of $ 75,000,000 of its ordinary shares that may be issued and sold under a sales agreement with H.C. Wainwright & Co in one or more at-the-market offerings. In 2018 and 2019,  no shares were issued pursuant to our ATM facility.

 

In September 2018, the Company consummated an underwritten public offering and concurrent registered direct offering of 6,612,500 ordinary shares at an issue price of $ 15.75 per share. The gross proceeds from this offering amounted to € 89,983,000 while the transaction costs amounted to € 5,792,000, resulting in net proceeds of € 84,191,000.

 

In October 2019, the Company consummated an underwritten public offering of 10,454,545 ordinary shares at an issue price of $ 5.50 per share. The gross proceeds from this offering amounted to €  51,597,000 while the transaction costs amounted to € 3,047,000, resulting in net proceeds of € 48,550,000.

In December 2019, the Company issued 371,306 shares in the aggregate amount of $3.5 million, at $9.43 (€8.51) per share to Ionis Pharmaceuticals, Inc. Under the terms of the agreement, the second installment of the upfront payment in ordinary shares to the Company’s common stock was made to Ionis upon the dosing of the first patient in the phase 1/2 Aurora clinical trial for QR-1123.

 

Translation reserve

The translation reserve comprises all foreign currency differences arising from the translation of the financial statements of foreign operations.

 

Share options

The Company operates an equity-settled share-based compensation plan, which was introduced in 2013. Options may be granted to employees, members of the Supervisory Board, members of the Management Board and consultants. The compensation expenses included in operating costs for this plan in the year ended December 31, 2019 were € 5,948,000 (2018: € 3,224,000), of which € 3,323,000 (2018: € 2,167,000) was recorded in general and administrative costs and € 2,625,000 (2018: € 1,057,000) was recorded in research and development costs.

9. Other income

Click or tap here to enter text.

 

 

 

 

 

 

 

 

 

 

 

Year ended December 31, 

 

 

 

 

 

 

    

2019

    

2018

 

 

€ 1,000

 

€ 1,000

 

 

 

 

 

Grant income

 

1,778

 

5,378

Other income

 

155

 

383

 

 

1,933

 

5,761

 

On February 9, 2018, the Company entered into a partnership agreement with Foundation Fighting Blindness (FFB), under which FFB has agreed to provide funding of $7.5 million for the pre-clinical and clinical development of QR‑421a for Usher syndrome type 2A targeting mutations in exon 13.

 

In addition, funding was received for our Huntington’s disease program.

 

Grants are recognized in other income in the same period in which the related R&D costs are recognized.

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM

 

Table of Contents

PAGE 10

Unaudited Condensed Consolidated Financial Statements

 

 

10. Research and development costs

Research and development costs amount to € 46,491,000 for the year ended December 31, 2019 (2018: € 29,514,000) and are comprised of allocated employee costs including share-based payments, the costs of materials and laboratory consumables, outsourced activities, license and intellectual property costs and other allocated costs.

11. General and administrative costs

General and administrative costs amount to € 12,887,000 for the year ended December 31, 2019 (2018: €  12,540,000).

12. Results related to associates

The results related to associates for the year ended December 31, 2019 amounting to € 429,000 (2018: € 0) consist of a gain on recognition of our investment in Wings Therapeutics Inc. for the amount of € 949,000, less our share of this entity’s net losses for the amount of € 520,000.

13. Income taxes

The current income tax liability amounts to € 64,000 at December 31, 2019.  No significant temporary differences exist between accounting and tax results. Realization of deferred tax assets is dependent on future earnings, if any, the timing and amount of which are uncertain. Accordingly, the Company has not yet recognized any deferred tax asset related to operating losses.

14. Events after balance sheet date

No significant events have occurred after the balance sheet date.

 

   PROQR THERAPEUTICS   

   ZERNIKEDREEF 9   

   2333 CK LEIDEN   

   THE NETHERLANDS   

   +31 88 166 7000   

   WWW.PROQR.COM